1
|
Thompson PA, Eam B, Young NP, Fish S, Chen J, Barrera M, Howard H, Sung E, Parra A, Staunton J, Chiang GG, Gerson-Gurwitz A, Wegerski CJ, Nevarez A, Clarine J, Sperry S, Xiang A, Nilewski C, Packard GK, Michels T, Tran C, Sprengeler PA, Ernst JT, Reich SH, Webster KR. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. Mol Cancer Ther 2021; 20:26-36. [PMID: 33037136 DOI: 10.1158/1535-7163.mct-19-0973] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 02/14/2020] [Accepted: 09/30/2020] [Indexed: 11/16/2022]
Abstract
The PI3K/AKT/mTOR pathway is often activated in lymphoma through alterations in PI3K, PTEN, and B-cell receptor signaling, leading to dysregulation of eIF4A (through its regulators, eIF4B, eIF4G, and PDCD4) and the eIF4F complex. Activation of eIF4F has a direct role in tumorigenesis due to increased synthesis of oncogenes that are dependent on enhanced eIF4A RNA helicase activity for translation. eFT226, which inhibits translation of specific mRNAs by promoting eIF4A1 binding to 5'-untranslated regions (UTR) containing polypurine and/or G-quadruplex recognition motifs, shows potent antiproliferative activity and significant in vivo efficacy against a panel of diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma models with ≤1 mg/kg/week intravenous administration. Evaluation of predictive markers of sensitivity or resistance has shown that activation of eIF4A, mediated by mTOR signaling, correlated with eFT226 sensitivity in in vivo xenograft models. Mutation of PTEN is associated with reduced apoptosis in vitro and diminished efficacy in vivo in response to eFT226. In models evaluated with PTEN loss, AKT was stimulated without a corresponding increase in mTOR activation. AKT activation leads to the degradation of PDCD4, which can alter eIF4F complex formation. The association of eFT226 activity with PTEN/PI3K/mTOR pathway regulation of mRNA translation provides a means to identify patient subsets during clinical development.
Collapse
Affiliation(s)
| | - Boreth Eam
- eFFECTOR Therapeutics, Inc., San Diego, California
| | | | - Sarah Fish
- eFFECTOR Therapeutics, Inc., San Diego, California
| | - Joan Chen
- eFFECTOR Therapeutics, Inc., San Diego, California
| | | | | | - Eric Sung
- eFFECTOR Therapeutics, Inc., San Diego, California
| | - Ana Parra
- eFFECTOR Therapeutics, Inc., San Diego, California
| | | | | | | | | | | | - Jeff Clarine
- eFFECTOR Therapeutics, Inc., San Diego, California
| | | | - Alan Xiang
- eFFECTOR Therapeutics, Inc., San Diego, California
| | | | | | | | - Chinh Tran
- eFFECTOR Therapeutics, Inc., San Diego, California
| | | | | | | | | |
Collapse
|
2
|
Parker GS, Hung IN, Staunton J, Barrera M, Sung E, Parra A, Stumpf CR, Chen J, Thompson PA, Nevarez A, Wegerski CJ, Clarine J, Sperry S, Xiang A, Nilewski C, Packard GK, Urklalan K, Mukaiyama T, Michels T, Ernst JT, Sprengeler PA, Reich SH, Chiang GG, Webster KR. Abstract B33: Targeting PI3K/mTOR signaling with potent, selective and orally-available small-molecule inhibitors of eIF4E. Mol Cancer Res 2020. [DOI: 10.1158/1557-3125.pi3k-mtor18-b33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aberrant protein translation plays a role in the pathogenesis of multiple solid tumors and hematologic malignancies. The translation initiation factor eIF4E is essential for the translation of m7G-capped mRNA and is a key point of convergence for several signaling pathways, such as PI3K/mTOR and MAPK, which are intimately involved in tumor cell growth and survival. As such, eIF4E has generated intense interest as a target for anticancer drug discovery. We have designed a series of potent, selective, and orally available m7G cap-competitive inhibitors of eIF4E (eFT-4Ei) with favorable drug-like properties. These inhibitors bind free eIF4E, eIF4E-4EBP and eIF4E-eIF4F complexes within tumor cells. Ribosomal profiling of eIF4E inhibitor-treated tumor cells has identified a subset of translationally regulated target genes that overlap with mTORC1/2 regulated genes, but also include a larger set of unique translationally regulated target mRNAs that are enriched for 5'-TOP, PRTE and CERT sequence elements in their 5'-untranslated regions. eIF4E inhibition results in potent antiproliferative activity and induction of apoptosis in a subset of tumor cell lines. Consistent with this observation, our eIF4E inhibitors show some similarities, yet several important differences from existing mTORC1 or mTORC1/2 dual inhibitors in both cellular and physiologic assays. Finally, significant antitumor efficacy was observed with eIF4E inhibition in both solid tumor and hematologic xenografts in vivo. Taken together, these results highlight the potential of targeting eIF4E as a novel and differentiated therapeutic strategy to treat cancer.
Citation Format: Gregory S. Parker, Ivy N.J. Hung, Jocelyn Staunton, Maria Barrera, Eric Sung, Ana Parra, Craig R. Stumpf, Joan Chen, Peggy A. Thompson, Andreas Nevarez, Christopher J. Wegerski, Jeff Clarine, Samuel Sperry, Alan Xiang, Christian Nilewski, Garrick K. Packard, Kaveri Urklalan, Takasuke Mukaiyama, Theo Michels, Justin T. Ernst, Paul A. Sprengeler, Siegfried H. Reich, Gary G. Chiang, Kevin R. Webster. Targeting PI3K/mTOR signaling with potent, selective and orally-available small-molecule inhibitors of eIF4E [abstract]. In: Proceedings of the AACR Special Conference on Targeting PI3K/mTOR Signaling; 2018 Nov 30-Dec 8; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(10_Suppl):Abstract nr B33.
Collapse
Affiliation(s)
| | | | | | | | - Eric Sung
- eFFECTOR Therapeutics, San Diego, CA
| | - Ana Parra
- eFFECTOR Therapeutics, San Diego, CA
| | | | - Joan Chen
- eFFECTOR Therapeutics, San Diego, CA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Nilewski C, Michels TD, Xiang AX, Packard GK, Sprengeler PA, Eam B, Fish S, Thompson PA, Wegerski CJ, Ernst JT, Reich SH. Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A Inhibitors. Org Lett 2020; 22:6257-6261. [DOI: 10.1021/acs.orglett.0c01944] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Christian Nilewski
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Theodore D. Michels
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Alan X. Xiang
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Garrick K. Packard
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Paul A. Sprengeler
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Boreth Eam
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Sarah Fish
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Peggy A. Thompson
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Christopher J. Wegerski
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Justin T. Ernst
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| | - Siegfried H. Reich
- eFFECTOR Therapeutics, 11180 Roselle Street, Suite A, San Diego, California 92121, United States
| |
Collapse
|
4
|
Chiang GG, Parker GS, Hung IN, Goel VK, Staunton J, Barrera M, Sung E, Parra A, Stumpf CR, Chen J, Thompson PA, Nevarez A, Wegerski CJ, Parker C, Clarine J, Sperry S, Xiang A, Nilewski C, Packard GK, Urkalan K, Mukaiyama T, Michels T, Ernst JT, Sprengeler PA, Reich SH, Webster KR. Abstract 1302: Targeting hormone receptor-dependent cancers with potent, selective and orally-available small molecule inhibitors of eIF4E. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The PI3K/mTOR pathway is commonly dysregulated in many hormone receptor-dependent tumors and plays a key role in promoting tumor growth and mediating drug resistance. In particular, PI3K and mTORC1/2 inhibitors have been intensively studied in the treatment of hormone receptor-dependent cancers and have shown benefit in some clinical settings. However, issues such as dose-limiting toxicities and emergent resistance limit the broader utility of these inhibitors. The translation initiation factor eIF4E is essential for the translation of m7G-capped mRNA and is a key point of convergence for both the PI3K/mTOR and MAPK signaling pathways. We have designed a series of potent, selective and orally-available m7G cap-competitive inhibitors of eIF4E (eFT-4Ei) with favorable drug-like properties. These inhibitors bind to eIF4E either as its free form or with eIF4E-4EBP and eIF4F complexes within tumor cells and downregulate hormone receptor-dependent signaling. Ribosomal profiling of eIF4E inhibitor-treated tumor cells identified a subset of translationally regulated target genes that overlap with mTORC1/2 regulated genes, but also a unique set of translationally regulated target mRNAs. Consistent with this observation, our eIF4E inhibitors show some similarities yet several important differences from existing mTORC1 or mTORC1/2 dual inhibitors in both cellular and physiological assays. Finally, significant anti-tumor efficacy was observed with eIF4E inhibition in vitro and in vivo. Taken together, these results highlight the potential for targeting eIF4E as a novel therapeutic strategy to treat hormone-receptor dependent cancers.
Citation Format: Gary G. Chiang, Gregory S. Parker, Ivy N. Hung, Vikas K. Goel, Jocelyn Staunton, Maria Barrera, Eric Sung, Ana Parra, Craig R. Stumpf, Joan Chen, Peggy A. Thompson, Andreas Nevarez, Christopher J. Wegerski, Cody Parker, Jeff Clarine, Samuel Sperry, Alan Xiang, Christian Nilewski, Garrick K. Packard, Kaveri Urkalan, Takasuke Mukaiyama, Theo Michels, Justin T. Ernst, Paul A. Sprengeler, Siegfried H. Reich, Kevin R. Webster. Targeting hormone receptor-dependent cancers with potent, selective and orally-available small molecule inhibitors of eIF4E [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1302.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Eric Sung
- eFFECTOR Therapeutics, San Diego, CA
| | - Ana Parra
- eFFECTOR Therapeutics, San Diego, CA
| | | | - Joan Chen
- eFFECTOR Therapeutics, San Diego, CA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Thompson PA, Eam B, Young NP, Fish S, Chen J, Barrera M, Howard H, Sung E, Parra A, Staunton J, Chiang GG, Wegerski CJ, Nevarez A, Clarine J, Sperry S, Xiang A, Tran C, Nilewski C, Packard GK, Michels T, Sprengeler PA, Ernst JT, Reich SH, Webster KR. Abstract 2698: eFT226, a potent and selective inhibitor of eIF4A, is efficacious in preclinical models of lymphoma. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2698] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Dysregulated messenger RNA (mRNA) translation drives the pathogenesis of multiple hematological malignancies. In lymphoma this includes the upregulation of key driver oncogenes and anti-apoptotic proteins (e.g., MYC, CCND1/3, BCL2 and MCL1) that contain a highly structured 5’-untranslated region (UTR) in their mRNA requiring enhanced eIF4A helicase activity for translation. eIF4A is a component of the eIF4F translation initiation complex and catalyzes the ATP-dependent unwinding of RNA duplexes and facilitates 43S ribosome scanning within the 5’-UTR. The activation of oncogenic signaling pathways, including RAS and PI3K, enhance eIF4A activity through phosphorylation of eIF4B, eIF4G and PDCD4 which facilitates formation of eIF4F and full activation of eIF4A. The PI3K/AKT/mTOR pathway is frequently activated in lymphoma, promoting the translation of oncogenes with complex 5’-UTRs that are required for tumor cell proliferation, survival and metastasis.
eFT226 is a potent and sequence selective eIF4A1 inhibitor that promotes eIF4A1 binding to specific 5’-UTR polypurine and/or G-quadraplex recognition motifs leading to a selective block in ribosome mRNA scanning. The sequence dependency of eFT226 translational inhibition was evaluated in cell-based reporter assays demonstrating >100-fold greater sensitivity for reporter constructs containing a polypurine motif in the 5’-UTR (IC50 ~2 nM). Direct binding studies also confirmed the formation of a stable ternary complex with increased drug residence time between eFT226, eIF4A1 and RNA oligonucleotides containing polypurine motifs. The ability of eFT226 to inhibit MYC or MCL1 expression was found to be dependent on the presence of their respective 5’-UTR supporting a translational regulation mechanism dependent on recognition elements within the 5’-UTR.
eFT226 shows potent anti-proliferative activity (GI50 < 15 nM) against a panel of B-cell lymphoma cell lines. Treatment with eFT226 leads to coordinated inhibition of MYC, CCND1/3, BCL2 or MCL1 protein expression resulting in significant anti-tumor activity. eFT226 has good pharmacokinetic properties and exhibits significant in vivo activity across a panel of diffuse large B cell lymphoma (DLBCL), and Burkitt lymphoma tumor models with ≤1 mg/kg/week IV administration. Further evaluation of predictive markers of sensitivity or resistance has shown that tumors with mTOR mediated activation of eIF4A are most sensitive to eFT226. In addition, tumors with PTEN mutations do not exhibit activated eIF4A and are generally resistant to induction of apoptosis by eFT226, resulting in reduced in vivo efficacy. The association of eFT226 activity with PI3K/mTOR pathway activation and mutational status provides a means to identify patient subsets during clinical development. Clinical trials in patients with lymphoma and other malignancies are planned.
Citation Format: Peggy A. Thompson, Boreth Eam, Nathan P. Young, Sarah Fish, Joan Chen, Maria Barrera, Haleigh Howard, Eric Sung, Ana Parra, Jocelyn Staunton, Gary G. Chiang, Christopher J. Wegerski, Andres Nevarez, Jeff Clarine, Samuel Sperry, Alan Xiang, Chinh Tran, Christian Nilewski, Garrick K. Packard, Theodore Michels, Paul A. Sprengeler, Justin T. Ernst, Siegfried H. Reich, Kevin R. Webster. eFT226, a potent and selective inhibitor of eIF4A, is efficacious in preclinical models of lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2698.
Collapse
Affiliation(s)
| | | | | | | | - Joan Chen
- eFFECTOR Therapeutics, San Diego, CA
| | | | | | - Eric Sung
- eFFECTOR Therapeutics, San Diego, CA
| | - Ana Parra
- eFFECTOR Therapeutics, San Diego, CA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Packard GK, Papa P, Riggs JR, Erdman P, Tehrani L, Robinson D, Harris R, Shevlin G, Perrin-Ninkovic S, Hilgraf R, McCarrick MA, Tran T, Fleming Y, Bai A, Richardson S, Katz J, Tang Y, Leisten J, Moghaddam M, Cathers B, Zhu D, Sakata S. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors. Bioorg Med Chem Lett 2012; 22:747-52. [DOI: 10.1016/j.bmcl.2011.03.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2011] [Revised: 02/28/2011] [Accepted: 03/02/2011] [Indexed: 01/08/2023]
|
7
|
Affiliation(s)
- Garrick K Packard
- Department of Chemistry, University of California, Irvine, 516 Rowland Hall, Irvine, CA 92697-2025, USA
| | | | | | | |
Collapse
|
8
|
Abstract
Polyene macrolide antibiotics are naturally occurring antifungal agents. Members of this class include amphotericin B, which has been used widely to treat systemic fungal infections. A general synthetic strategy has been devised to prepare polyol chains associated with the polyene macrolides. Cyanohydrin acetonide alkylations were used to assemble the carbon skeleton, and a simple modification of the strategy allowed an advanced intermediate to be converted to either the candidin polyol or the nystatin polyol. The candidin polyol was further elaborated to a protected candidin aglycone. This strategy will be applicable to other members of the polyene macrolide natural products.
Collapse
Affiliation(s)
- Isao Kadota
- Department of Chemistry, University of California, Irvine, CA 92697-2025, USA
| | | | | | | |
Collapse
|
9
|
|
10
|
Abstract
[reaction: see text]. Both an intramolecular aglycon delivery (IAD) method and an intermolecular S(N)2 displacement method were examined for beta-selective glycosylations of cholesterol with D-mycosamine. An anomeric sulfoxide, sulfide, selenide, and fluoride were all successfully used as glycosyl donors in IAD reactions. The alpha-bromo ketone 19 was synthesized from protected mycosamine and employed in an intermolecular S(N)2 glycosylation reaction. Both routes were successful for the model alcohol, cholesterol.
Collapse
Affiliation(s)
- G K Packard
- Department of Chemistry, University of California, Irvine, California, 92697-2025, USA
| | | |
Collapse
|